Potential missed opportunities to improve long-term liver allograft health

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Long-term outcomes after liver transplantation are limited by alloimmune issues, cancer, and metabolic syndrome complications.
• Current immunosuppression strategies can worsen these long-term problems.
• Emerging evidence suggests repurposed drugs may offer benefits.

Purpose of the Study:

• To explore the potential of FDA-approved and investigational drugs to improve long-term patient and allograft health post-liver transplant.
• To identify interventions that address both metabolic and immune pathways impacting transplant outcomes.

Main Methods:

• Review of emerging evidence on pharmacologic interventions.
• Analysis of mechanisms of action for agents including HMG-coA-reductase inhibitors, aspirin, obesity/NASH treatments, and microbiome interventions.
• Assessment of potential off-label benefits in the liver transplant context.

Main Results:

• These agents may reduce chronic liver injury complications through anti-inflammatory, metabolic improvement, immune tolerance, and anti-fibrotic effects.
• A multifaceted approach targeting metabolic and immune pathways shows promise.
• Potential to enhance allograft and patient health beyond current standards.

Conclusions:

• Pharmacologic interventions targeting metabolic and immune pathways represent a novel strategy for optimizing long-term liver transplant outcomes.
• Further clinical research is essential to establish the efficacy and safety of these agents in liver transplant recipients.
• Repurposing existing and investigational drugs could significantly improve post-transplant care.